NF-[kappa]B is Not Directly Responsible for Photoresistance Induced by Fractionated Light Delivery in HT-29 Colon Adenocarcinoma Cells

Our recent study follows up an earlier one which demonstrated hypericin-mediated photocytotoxic effects on HT-29 adenocarcinoma cells by light fractionation with a longer dark pause between two unequal light doses (Sackova, A. [2005] Photochem. Photobiol. 81, 1411-1416). Here, we present closer stud...

Full description

Saved in:
Bibliographic Details
Published inPhotochemistry and photobiology Vol. 86; no. 6; p. 1285
Main Authors Kuliková, Lucia, Mikes, Jaromír, Hyzdalová, Martina, Palumbo, Giuseppe, Fedorocko, Peter
Format Journal Article
LanguageEnglish
Published Lawrence Blackwell Publishing Ltd 01.11.2010
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Our recent study follows up an earlier one which demonstrated hypericin-mediated photocytotoxic effects on HT-29 adenocarcinoma cells by light fractionation with a longer dark pause between two unequal light doses (Sackova, A. [2005] Photochem. Photobiol. 81, 1411-1416). Here, we present closer study on events invoked by sublethal light dose (1 J cm^sup -2^) during the period of 6 h that is sufficient to invoke resistance to second lethal dose (11 J cm^sup -2^). First, we proved that the dark pause of 6 h, but not 1 h, resulted in better cell survival with suppressed phosphatidylserine externalization, decreased reactive oxygen species production and hypericin content as well as altered expression of HSP70, GRP94, clusterin, nuclear factor (NF)-κB, IκB-α or Mcl-1. NF-κB activity assay confirmed activation of this early-response pathway. However, inhibition of IκB (IKK) kinase by parthenolide by stopping NF-κB release from the complex with IκB did not prevent onset of resistance, but it invoked sonic resistance even in groups with shorter, 1 h dark pause. Therefore, we predict involvement of another signaling pathway, located upstream from NF-κB, responsible for onset of resistance to photodynamic therapy with hypericin in colon adenocarcinoma cells HT-29. [PUBLICATION ABSTRACT]
ISSN:0031-8655
1751-1097